Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
GSK plc American Depositary Shares (Each representing two Ordinary Shares)
(NY:
GSK
)
51.46
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Aug 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
45
46
Next >
Peering Into GSK's Recent Short Interest
↗
August 29, 2023
Via
Benzinga
3 Growth Stocks to Ride the Coming Bull Market in Style
↗
August 26, 2023
Bull markets always follow bear markets, and these three companies are growth stocks to buy for the next wave higher
Via
InvestorPlace
3 Sorry Pharma Stocks to Sell in August Before It’s Too Late
↗
August 22, 2023
Factors in the marketplace caused these companies to underperform, making them some of the top pharma stocks to sell.
Via
InvestorPlace
FDA Greenlights Pfizer's RSV Vaccine: Moms Can Now Protect Babies Before Birth
↗
August 22, 2023
Monday, the FDA approved Pfizer Inc's (NYSE: PFE) Abrysvo (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, to prevent the infection in infants from birth...
Via
Benzinga
GSK Announces AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Is Now Available at All Major US Retail Pharmacies
August 17, 2023
From
GSK plc
Via
Business Wire
Looking Into GSK's Recent Short Interest
↗
August 04, 2023
Via
Benzinga
A Look Into GSK Inc's Price Over Earnings
↗
August 03, 2023
Via
Benzinga
Is GSK an Excellent Dividend Stock to Buy for Passive Income Investors?
↗
August 14, 2023
GSK offers a robust dividend yield, but that's not the only thing to consider.
Via
The Motley Fool
3 Pharma Stocks to Sell in August Before They Crash and Burn
↗
August 11, 2023
Stay far away from these pharma stocks that are suffering from declining sales and weak pipelines of future products.
Via
InvestorPlace
GSK, Pfizer Lock Horns Over Patent Fight Related To Respiratory Syncytial Virus Vaccine
↗
August 02, 2023
GSK Plc (NYSE: GSK) has sued Pfizer Inc (NYSE: PFE) in Delaware court, alleging that Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violates GSK's four patent rights in its RSV
Via
Benzinga
GSK's Jemperli Plus Chemo Combo Scores FDA Approval As First New Frontline Treatment For Certain Type Of Endometrial Cancer
↗
August 01, 2023
The FDA approved GSK plc's (NYSE: GSK) Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for primary advanced or recurrent endometrial cancer...
Via
Benzinga
Jemperli (dostarlimab-gxly) plus chemotherapy approved in the US as the first new frontline treatment option in decades for dMMR/MSI-H primary advanced or recurrent endometrial cancer
July 31, 2023
From
GSK plc
Via
Business Wire
Is GSK Stock Worth Buying Right Now?
↗
July 29, 2023
GSK stock could be a bargain.
Via
The Motley Fool
A Look Into GSK's Debt
↗
July 17, 2023
Via
Benzinga
If You Can Only Buy One Dividend Stock, It Better Be One of These 7 Names
↗
July 30, 2023
Here are seven of the best dividend stocks to consider immediately. Better, each of these stocks have strong, stable businesses.
Via
InvestorPlace
3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes
↗
July 30, 2023
Here are three millionaire maker drug stocks from companies whose drugs could make truly staggering profits.
Via
InvestorPlace
GSK Says 'Excellent' Q2 Performance Boosted By Vaccine & HIV Drug Sales, Raises 2023 Outlook
↗
July 26, 2023
GSK plc (NYSE: GSK) reported Q2 FY23 sales of £7.18 billion ($8.97 billion), up 4% Y/Y on t
Via
Benzinga
Pharma Giant GSK Beats Second-Quarter Goals On Growth In Vaccines, General Medicines
↗
July 26, 2023
Pharmaceutical giant GSK beat expectations for the second quarter and raised its forecast for the full year. GSK stock rose on the news.
Via
Investor's Business Daily
Tesla's India Move, Adidas Receives Orders For Massive Unsold Yeezy Inventory, Spotify Raises Subscription Prices: Today's Top Stories
↗
July 24, 2023
Wall Street Journal
Via
Benzinga
GSK's RSV Vaccine Scores Approval In UK For Older Adults
↗
July 10, 2023
The U.K.
Via
Benzinga
GSK-Pfizer Backed HIV-Focused Unit ViiV Healthcare's Cabotegravir Injected Drug, Tablets Secure European Backing For Approval
↗
July 24, 2023
ViiV Healthcare received a positive opinion from the European Medicines Agen
Via
Benzinga
The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023
↗
July 21, 2023
Trading below a 15 forward price-to-earnings, these undervalued pharma stocks offer opportunities in an overbought market.
Via
InvestorPlace
Why Shares of Vir Biotechnology Are Plunging Thursday
↗
July 20, 2023
The company had disappointing trial news for one of its lead therapies.
Via
The Motley Fool
Intercept Pharma Gets Double Upgrade: Analyst Says OCA Combo Therapy Can Extend PBC Business
↗
July 13, 2023
HC Wainwright has upgraded Intercept Pharmaceuticals Inc (NASDAQ: ICPT) to Buy from Sell, with a price target of
Via
Benzinga
7 Stocks That AI Says Will Make You a Millionaire by 2025
↗
July 13, 2023
These seven millionaire-maker stocks are changing hands at deeply undervalued levels. As their growth re-accelerates, so will your portfolio.
Via
InvestorPlace
3 Healthcare Stocks With Healthy Dividends
↗
July 13, 2023
These pharmaceutical companies all combine relatively high dividends with safe payout ratios.
Via
The Motley Fool
GSK is first to ship influenza vaccine doses for the 2023-24 flu season in US
July 13, 2023
From
GSK plc
Via
Business Wire
3 No-Brainer Stocks to Buy With $50 Right Now
↗
July 12, 2023
You don't need a treasure chest full of cash to begin building wealth on Wall Street.
Via
The Motley Fool
Why Are NanoViricides Shares Gaining Today
↗
July 11, 2023
NanoViricides Inc (NYSE: NNVC) shares are trading higher after the company reported preclinical data from an antiviral clinical drug candidate for
Via
Benzinga
Meta's Threads Hits 100M Users In Five Days, Foxconn Pulls Out From $19.5B Semiconductor India JV, Novo Nordisk's Weight-Loss Medications Under European Investigation Over Suicidal Risks: Today's Top Stories
↗
July 10, 2023
Benzinga
Via
Benzinga
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
45
46
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.